三鑫醫療(300453.SZ)：2020年淨利升87.45%至1.16億元 擬10送1.5轉3.5派2元
格隆匯3月26日丨三鑫醫療(300453.SZ)披露2020年年度報吿，實現營業收入9.4億元，同比增長30.31%；歸屬於上市公司股東的淨利潤1.16億元，同比增長87.45%；歸屬於上市公司股東的扣除非經常性損益的淨利潤1.01億元，同比增長87.54%；基本每股收益0.45元，擬向全體股東每10股派發現金紅利2元(含税)，送紅股1.5股(含税)，以資本公積金向全體股東每10股轉增3.5股。
報吿期內，公司業務主要體現在以下幾大領域。
血液淨化類：報吿期內，公司提前復工復產，血液淨化類產品保持了良好的生產經營狀況，血液淨化類產品實現銷售收入5.83億元，比上年同期增長29.51%，繼續保持了較好的增長態勢，該類產品銷售收入佔公司總收入的62.01%。
留置導管類：報吿期內，留置導管類產品實現銷售收入7119.49萬元，比上年同期下降3.79%，該類產品銷售收入佔公司總收入的7.57%。
注射類：報吿期內，注射類產品實現銷售收入7536.00萬元，比上年同期下降4.97%，該類產品銷售收入佔公司總收入的8.01%。
輸液輸血類：報吿期內，輸液輸血類產品實現銷售收入6467.06萬元，比上年同期下降11.86%，該類產品銷售收入佔公司總收入的6.88%。
心胸外科類：報吿期內，心胸外科類產品實現營業收入5741.95萬元，比上年同期增長74.00%，該類產品銷售收入佔公司總收入的6.11%(寧波菲拉爾自2019年7月起納入公司合併報表範圍)。
防護類：報吿期內，防護類產品實現銷售收入7721.57萬元(新增)，該類產品銷售收入佔公司總收入的8.21%。
不斷加大血液淨化類產品市場開拓力度
報吿期內，公司繼續加大血液淨化類產品的市場開拓力度，積極參與各地區集中採購，其中一次性使用空心纖維血液透析器完成銷量300多萬支，較上年同期增長34.23%，血液透析設備完成銷量300多台，較上年同期增長160%，未來公司將持續加大對血液淨化類產品的市場開拓力度，提升公司產品市場佔有率。
江西製造基地技術改造完成，擴充血液透析濃縮液產能
報吿期內，公司江西製造基地完成血液透析濃縮液的技術改造，產能得到了進一步提升，公司及子公司血液透析濃縮液產能已增加至1800萬人份/年。隨着四川威力生血液透析濃縮液產品註冊證獲證在即，公司及子公司血液透析濃縮液產品的產能將超過2000萬人份/年。
設立子公司，提升產業協同效應
報吿期內，公司在中國(南昌)中醫藥科創城投資設立子公司江西聖丹康，江西聖丹康將致力於利用中醫藥優勢對慢性腎病等進行前置管理，充分發揮公司行業影響力和產品競爭優勢，提升產業協同效應，延伸公司血液淨化產業鏈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
